The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
Status:
Recruiting
Trial end date:
2027-11-21
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to determine if positive pressure during inspiration will
improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the
lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD).
The main questions it aims to answer are:
- Does delivery of aerosolized NAC with positive inspiratory pressure have a greater
effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.
- Does delivery of aerosolized NAC with positive inspiratory pressure have a greater
effect on lung function than delivery of NAC without positive pressure.
Participants will be assigned (in a single blind design) to the NAC via jet nebulizer group
or the NAC via AeroEclipse-VersaPAP nebulizer group. Participants will each complete 5
treatment visits over the course of 30 days. Each treatment visit will consist of two
treatments of a 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by
4 hours, via the nebulization method specific to their group.